Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 21;8(57):32770-32774.
doi: 10.1039/c8ra06050a. eCollection 2018 Sep 18.

Unlocked nucleic acid modified primer-based enzymatic polymerization assay: towards allele-specific genotype detection of human platelet antigens

Affiliations

Unlocked nucleic acid modified primer-based enzymatic polymerization assay: towards allele-specific genotype detection of human platelet antigens

Bao T Le et al. RSC Adv. .

Abstract

Accurate detection of single nucleotide polymorphisms (SNPs) is paramount for the appropriate therapeutic intervention of debilitating diseases associated with SNPs. However, in some cases current nucleic acid probes fail to detect allele-specific mutations, for example, human platelet antigens, HPA-15a (TCC) and HPA-15b (TAC) alleles associated with neonatal alloimmune thrombocytopenia. Towards this, it is necessary to develop a novel assay for detection of allele-specific mutations. In this study, we investigated the potential of unlocked nucleic acid (UNA)-modified primers in SNP detection utilising an enzymatic polymerisation-based approach. Our results of primer extension and asymmetric polymerase chain reaction by KOD XL DNA polymerase revealed that UNA-modified primers achieved excellent allele-specificity in discriminating the human platelet antigen DNA template, whereas the DNA control primers were not able to differentiate between the normal and mutant alleles, demonstrating the scope of this novel UNA-based enzymatic approach as a robust methodology for efficient detection of allele-specific mismatches. Although further evaluation is required for other disease conditions, we firmly believe that our findings offer a great promise for the diagnosis of neonatal alloimmune thrombocytopenia and other SNP-related diseases.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Fig. 1
Fig. 1. Structural representations of RNA, UNA and LNA nucleotide monomers.
Fig. 2
Fig. 2. Primer extension assay of (A) P1 annealed to templates T1, T2 and T3; (B) P2-UNA-A5 annealed to templates T1, T2 and T3; (C) P3-UNA-C7 annealed to templates T1, T2 and T3; (D) gel images of extension products from (A), (B) and (C) respectively; lane 1: P1 alone, lane 2: P2-UNA-A5 alone, lane 3: P3-UNA-C7 alone. UNA nucleotides are represented in underlined letters with superscript “U”; mismatched nucleotides are represented in lower-case underlined italic letters. All primers are labelled with 5′-FAM. Full sequence of template T1, T2 and T3 are shown in ESI Table S1. Gel images were cropped and demonstrated as (D), for original gel images please see ESI Fig. S1.
Fig. 3
Fig. 3. Primer extension assays of (A): DNA (P4 and P5) and UNA-modified primers (P6-UNA-C7–P11-UNA-A2) annealed to template T4; (C) DNA (P4 and P5) and UNA-modified primers (P6-UNA-C7–P11-UNA-A2) annealed to template T5; (B) and (D) gel images from (A) and (C), respectively. UNA nucleotides are represented in underlined letters with superscript “U”; mismatched nucleotides are represented in lower-case underlined italic letters. All primers are labelled with 5′-FAM. Full sequence of template T4 and T5 are shown in ESI Table S1.
Fig. 4
Fig. 4. Asymmetric PCR assays using DNA and UNA-modified primers. (A): template T4 and (B): template T5. For both (A and B): lane 1: P4; lane 2: P5; lane 3: P6-UNA-C7; lane 4: P7-UNA-C6; lane 5: P8-UNA-U5; lane 6: P9-UNA-G4; lane 7: P10-UNA-U3; lane 8: P11-UNA-A2.

Similar articles

References

    1. Deleavey G. F. Damha M. J. Chem. Biol. 2012;19:937–954. doi: 10.1016/j.chembiol.2012.07.011. - DOI - PubMed
    1. Bao T. L. Veedu R. N. Fletcher S. Wilton S. D. Expert Opin. Orphan Drugs. 2015;4:139–152. doi: 10.1517/21678707.2016.1122517. - DOI
    1. Pasternak A. Wengel J. Org. Biomol. Chem. 2011;9:3591–3597. doi: 10.1039/C0OB01085E. - DOI - PubMed
    1. Langkjær N. Pasternak A. Wengel J. Bioorg. Med. Chem. 2009;17:5420–5425. doi: 10.1016/j.bmc.2009.06.045. - DOI - PubMed
    1. Campbell M. A. Wengel J. Chem. Soc. Rev. 2011;40:5680–5689. doi: 10.1039/C1CS15048K. - DOI - PubMed